Bluefin Achieves Girocard Certification for the Newland Payment Technology N950 AIO smartPOS
18.2.2025 15:00:00 CET | Business Wire | Press release
Bluefin has achieved the German Banking Industry Committee’s (GBIC German: Deutsche Kreditwirtschaft) Girocard certification on the Newland NPT N950 AIO smartPOS terminal. This certification enables German merchants to adopt next-generation SmartPOS devices while simplifying Girocard payment acceptance through Bluefin’s TECS Engine, a global payments platform.
Bluefin’s TECS Engine provides omnichannel payment solutions to Acquirers, Payment Service Providers, POS system providers, Independent Software Vendors (ISVs) and other merchant aggregators around the globe offering a cloud-based Payments Platform-as-a-Service, including Bluefin’s payment and data security solutions, P2PE and universal tokenization.
As the leading debit card in Germany, Girocard conducted 7.5 billion transactions in 2023. With Girocard certification on the Newland N950 AIO smartPOS terminal, the German market will benefit from an open platform with access to new generations of SmartPOS devices and streamlined Girocard payment acceptance while benefitting from lower merchant service fees.
“Achieving Girocard certification for the Newland N950 AIO smartPOS is a key milestone for TECS and Bluefin, reinforcing our commitment to delivering secure, innovative, and globally adaptable payment solutions,” said Anton Scheiber, International Sales & Business Development Director, Bluefin. “This certification provides new opportunities for merchants in Germany, giving them access to innovative SmartPOS technology while ensuring seamless Girocard payment acceptance.”
The Newland N950 is an Android SmartPOS terminal designed for seamless and secure payments across industries like retail, hospitality, and dining. Featuring a sleek touchscreen display and support for multiple payment methods – including chip and PIN, contactless, NFC, and QR-code payments – the N950 enhances customer engagement while streamlining transactions.
“We are excited to partner with Bluefin to bring the Newland N950 to the German market with Girocard certification,” said Kazem Aminaee, International President at Newland Payment Technology. “As a next-generation SmartPOS solution, the N950 combines advanced payment technology with a flexible platform, empowering businesses to enhance their payment experience while supporting Germany’s leading domestic debit card.”
About Bluefin
Bluefin is the recognized integrated payments leader in encryption and tokenization technologies that protect payments and sensitive data. Our product suite includes solutions for contactless, face-to-face, call center, mobile, E-commerce and unattended payments and data in the healthcare, higher education, government and nonprofit industries. The company’s 300 global partners serve 35,000 connected enterprise and software clients operating in 60 countries. Bluefin is a Participating Organization (PO) of the PCI Security Standards Council (SSC) and is headquartered in Atlanta, with offices in Waterford, Ireland and Vienna, Austria. For more information, visit https://www.bluefin.com/.
About Newland NPT
Newland NPT (Newland Payment Technology) is a leading global provider of payment acceptance technology. With over 30 years’ experience supplying best-in-class solutions, and working with partners in over 120 countries, Newland has successfully deployed over 100 million payment devices worldwide. For more information, visit https://www.newlandnpt.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218500456/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom